Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05611528 | Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia | PHASE3 | COMPLETED | 10 | — | — | Feb 21, 2023 | Mar 18, 2025 | Mar 25, 2025 | 1 | Canada |
Change in total cholesterol, LDL-Cholesterol, HDL-Cholesterol, triglyceride, non-HDL-Cholesterol and apolipoprotein B plasma concentration
| Arm | Type | Description |
|---|---|---|
| Evinacumab-treated patients | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Evinacumab | DRUG | Evinacumab 15 mg/kg administered intravenously every 4 weeks |
Inclusion Criteria: * HoFH patients having been previously or being currently treated with evinacumab or clinical diagnosis of HoFH requiring additional lipid lowering therapy. Exclusion Criteria: * Any new condition or worsening of an existing condition, which in the opinion of the investigator ...